HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:
Sign In to gain access to subscriptions and/or personal tools.

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Request Reprints Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (10) Citing Articles via Google Scholar Google Scholar Articles by Pennick, M. Articles by Damment, S. J. P. Search for Related Content PubMed PubMed Citation Articles by Pennick, M. Articles by Damment, S. J. P. Social Bookmarking                         What's this?

Absolute Bioavailability and Disposition of Lanthanum in Healthy Human Subjects Administered Lanthanum Carbonate

From Shire Pharmaceutical Development Ltd, Basingstoke, Hampshire, United Kingdom.

Lanthanum carbonate [La₂(CO₃)₃] is a noncalcium, non-aluminum phosphate binder indicated for hyperphosphatemia treatment in end-stage renal disease. A randomized, open-label, parallel-group, phase I study was conducted to determine absolute bioavailability and investigate excretory routes for systemic lanthanum in healthy subjects. Twenty-four male subjects were randomized to a single lanthanum chloride (LaCl₃) intravenous infusion (120 µg elemental lanthanum over a 4-hour period), a single 1-g oral dose [chewable La₂(CO₃)₃ tablets; 4 x 250 mg elemental lanthanum], or no treatment (control). Serial blood, urine, and fecal samples were collected for 7 days postdosing. The absolute bioavailability of lanthanum [administered as La₂(CO₃)₃] was extremely low (0.00127% ± 0.00080%), with individual values in the range of 0.00015% to 0.00224%. Renal clearance was negligible following oral administration (1.36 ± 1.43 mL/min). Intravenous administration confirmed low renal clearance (0.95 ± 0.60 mL/min), just 1.7% of total plasma clearance. Fecal lanthanum excretion was not quantifiable after intravenous administration owing to high and variable background fecal lanthanum and constraints on the size of the intravenous dose. These findings demonstrate that lanthanum absorption from the intestinal tract into the systemic circulation is extremely low and that absorbed drug is cleared predominantly by nonrenal mechanisms.

Key Words: Lanthanum • bioavailability • human

Address for reprints: BDL, 26 Woodfield Lane, Ashtead, Surrey, KT21 2BE, UK; e-mail: enquiries{at}bdl-online.com.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				P. D'Haese and S. J. P. Damment Comment on 'Lanthanum deposition in a dialysis patient' Nephrol. Dial. Transplant., January 1, 2010; 25(1): 314 - 314. [Full Text] [PDF]

				C. Muller, F. Chantrel, and B. Faller A confusional state associated with use of lanthanum carbonate in a dialysis patient: a case report Nephrol. Dial. Transplant., October 1, 2009; 24(10): 3245 - 3247. [Abstract] [Full Text] [PDF]

				A. J. Hutchison, M. Laville, and on behalf of the SPD405-313 Lanthanum Study Group Switching to lanthanum carbonate monotherapy provides effective phosphate control with a low tablet burden Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3677 - 3684. [Abstract] [Full Text] [PDF]

				P. P. How, D. L. Mason, and A. H. Lau Current Approaches in the Treatment of Chronic Kidney Disease Mineral and Bone Disorder Journal of Pharmacy Practice, June 1, 2008; 21(3): 196 - 213. [Abstract] [PDF]